Interesting list of partners...
MUNICH, Germany, Nov. 27 /PRNewswire/ -- GPC Biotech AG (Frankfurt Stock Exchange: GPC), a leading genomics and proteomics-based drug discovery company, today announced that it has licensed key intellectual property covering a novel technology for protein-protein interaction studies from California Institute of Technology/CalTech (Pasadena, California USA) and Garching Innovation, licensing agent for the Max-Planck-Gesellschaft (both Munich, Germany). The Detection Enhanced Ubiquitin Split Protein Sensor (DEUS-PS) technology is comprised of two issued US patents and pending patent applications as well as know-how from the two licensees. The rights to this innovative protein-protein interaction technology provide GPC Biotech with a competitive advantage in the field of molecular pathway mapping. GPC Biotech will utilize the licensed technology together with its proprietary proteomics technologies, both for internal product development and in its research and drug discovery alliances.
Together with GPC Biotech's automation expertise and its existing PathCode(TM) technology, the DEUS-PS technology will broaden GPC Biotech's existing proteomics platform. This extended platform provides a highly sensitive and versatile system that can be used to investigate protein-protein interactions in diverse cellular host systems, including yeast and mammalian cells. In addition, and in contrast to other commonly used interaction screening systems such as the yeast-two-hybrid technology, the DEUS-PS technology accommodates the analysis of protein-protein interactions in diverse cellular compartments, e.g., the cytoplasm or in membranes. This overcomes some of the significant limitations of existing protein interaction technologies. Based on its distinct features, the DEUS-PS technology represents a unique and powerful expansion of GPC Biotech's proteomics capabilities. The analysis of proteins and their interactions is key to the understanding of the molecular basis of disease, the pathways that are affected by them, and therefore also the drug discovery process.
GPC Biotech AG is a genomics and proteomics-driven drug discovery company focused on applying a number of proprietary genomic, proteomic and drug discovery technologies to accelerate the identification and validation of novel drug targets for development of mechanism-based drugs in oncology, infectious diseases and immunology. GPC Biotech has leading cell cycle expertise and a broad intellectual property position with 47 patents issued and over 150 patents pending. Drug discovery alliance partners include: Aventis Pharma, Bayer AG, DuPont Pharmaceuticals, Boehringer Ingelheim, the Altana AG subsidiary Byk Gulden, Cell Genesys, Maxim Pharmaceuticals, Evotec Biosystems AG, Morphosys AG and Karo Bio USA. GPC Biotech AG is headquartered in Munich (Germany) with US subsidiaries in Cambridge, MA and in Princeton, NJ. For further information, please visit the corporate website at: gpc-biotech.com ..... |
